![Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial β extend AI; GIM trial longer results ππ» to dose dense and ππ»to add 5οΈβ£FU; ADAPT trial and ADAPTcycle ππ»to Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial β extend AI; GIM trial longer results ππ» to dose dense and ππ»to add 5οΈβ£FU; ADAPT trial and ADAPTcycle ππ»to](https://pbs.twimg.com/media/FcSQ_uAWAAA51_R.jpg)
Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial β extend AI; GIM trial longer results ππ» to dose dense and ππ»to add 5οΈβ£FU; ADAPT trial and ADAPTcycle ππ»to
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
![JCM | Free Full-Text | Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges JCM | Free Full-Text | Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges](https://pub.mdpi-res.com/jcm/jcm-12-00953/article_deploy/html/images/jcm-12-00953-g001-550.jpg?1675653487)
JCM | Free Full-Text | Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
![Cancers | Free Full-Text | Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy Cancers | Free Full-Text | Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy](https://www.mdpi.com/cancers/cancers-14-06237/article_deploy/html/images/cancers-14-06237-g004.png)
Cancers | Free Full-Text | Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
![Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | npj Breast Cancer Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-020-0155-1/MediaObjects/41523_2020_155_Fig1_HTML.png)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | npj Breast Cancer
![Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2022/esmo-congress-paris/ea/2022-esmo-cf_ea_thumbnails_1024x576/2022-esmo-cf_ea_thumb-11.png?rev=85ac26b259c64a70a4614f4fb58fb83e)
Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options
![ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1662802246792806815631c5946e4934.png)
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
![PDF) Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894) PDF) Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894)](https://i1.rgstatic.net/publication/363763112_Preoperative_robotic_radiosurgery_for_early_breast_cancer_results_of_the_phase_II_ROCK_trial_NCT03520894/links/632d04268a308c74009825eb/largepreview.png)
PDF) Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894)
![Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2022/esmo-congress-paris/ea/2022-esmo-cf_ea_thumbnails_1024x576/2022-esmo-cf_ea_thumb-10.png?rev=59e270b460cd4ca6abf7e7512d80819a)
Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options
![Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-68205-w/MediaObjects/41598_2020_68205_Fig1_HTML.png)
Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model | Scientific Reports
![Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2022/esmo-congress-paris/ea/2022-esmo-cf_ea_thumbnails_1024x576/2022-esmo-cf_ea_thumb-4.png?rev=1cc708d4e63d4248ac1829b593c483ed)
Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options
![Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BEL... | OncologyPRO Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BEL... | OncologyPRO](https://www.esmo.org/bundles/app/images/logos/esmo_logo.png)
Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BEL... | OncologyPRO
![Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance - ScienceDirect Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2667005421000296-gr2.jpg)
Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance - ScienceDirect
![ICIs Exhibit Activity in Triple-Negative Breast Cancer With Higher TIL Levels - Cancer Therapy Advisor ICIs Exhibit Activity in Triple-Negative Breast Cancer With Higher TIL Levels - Cancer Therapy Advisor](https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2022/05/Medical-vials_G_1195013067.jpg)
ICIs Exhibit Activity in Triple-Negative Breast Cancer With Higher TIL Levels - Cancer Therapy Advisor
![Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial β extend AI; GIM trial longer results ππ» to dose dense and ππ»to add 5οΈβ£FU; ADAPT trial and ADAPTcycle ππ»to Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial β extend AI; GIM trial longer results ππ» to dose dense and ππ»to add 5οΈβ£FU; ADAPT trial and ADAPTcycle ππ»to](https://pbs.twimg.com/media/FcSQ_t-XkAIf0uF.jpg)
Jose Fernando Moura, PhD on Twitter: "#esmo22 proffered abstracts # breastcancer DATA trial β extend AI; GIM trial longer results ππ» to dose dense and ππ»to add 5οΈβ£FU; ADAPT trial and ADAPTcycle ππ»to
![A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia](https://www.clinical-lymphoma-myeloma-leukemia.com/cms/asset/7345ec3c-af4f-4962-98c2-4c673d27d308/gr1.jpg)
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma - Clinical Lymphoma, Myeloma and Leukemia
![Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2022/esmo-congress-paris/ea/2022-esmo-cf_ea_thumbnails_1024x576/2022-esmo-cf_ea_thumb-13.png?rev=b90edd08e213463f957f70ca30f192b3)
Breast Cancer - ESMO 2022 Highlights - Expert Analysis - ESMO 2022 - Oncology - Clinical Care Options
![ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial](https://larvolclin.s3.us-west-2.amazonaws.com/16628021841053073353631c5908a3634.png)
ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial
![ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial ESMO 2022: Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16628056931341866482631c66bd758ce.png)